Skip to main content
Top
Published in: Abdominal Radiology 7/2021

Open Access 01-07-2021 | Metastasis | Hepatobiliary

Screening of radiotracer for diagnosis of colorectal cancer liver metastasis based on MACC1-SPON2

Authors: Hao Jiang, Wei Guo, Kuan Huang, Huijie Jiang, Rongjun Zhang, Hongbo Hu, Xue Lin, Song Wang

Published in: Abdominal Radiology | Issue 7/2021

Login to get access

Abstract

Background

Metastasis-associated in colon cancer 1 (MACC1) and Spondin2 (SPON2) are newly discovered oncogenes, but little is known about their role in colorectal cancer(CRC) liver metastases. PET has become an important molecular imaging technology due to its high sensitivity and quantifiability. In particular, its targeted, specific molecular probes can detect biological behaviors. This study was designed to evaluate the different biological properties of 18F-FDG, 18F-FLT, and 18F-FMISO PET. The value of the CRC liver metastasis model explores the correlation and potential mechanisms of three tracers uptakes with tumor-related biological characteristics.

Methods

Human CRC cell lines(LoVo and HCT8), were cultured for in vitro radionuclide uptake experiments to compare the molecular imaging features of colorectal cancer cells with different metastatic potentials. Two kinds of cells were injected into the spleen of nude mice to establish a liver metastasis model. After the tumor formation, three kinds of tracer PET images were performed to evaluate the characteristics of live PET imaging of high and low liver metastasis colorectal cancer models. The expression levels of MACC1 and SPON2 in tissues were detected by immunohistochemistry and Western blot. Correlation between tracer uptake and expression of MACC1 and SPON2 in liver metastases was assessed by linear regression analysis.

Results

The uptake rate of in vitro three tracers uptake experiments was LoVo > HCT8. Micro-PET scan showed no significant difference between the 18F-FDG SUV values of the two cells (P > 0.05); there was significant difference between the 18F-FLT and 18F-FMISO SUV values (P < 0.05). All in vivo FLT and FMISO SUV values were significantly higher in LoVo tumors than in HCT8 tumors. The results of Western blot and immunohistochemistry showed that the expression levels of MACC1 and SPON2 in LoVo liver metastasis were higher than those in HCT8 (P < 0.05). The 18F-FLT SUVmax ratio was significantly correlated with the expression of MACC1 and SPON2 in hepatic metastases (r = 0.737, P = 0.0026; r = 0.842, P = 0.0002). The 18F-FMISO SUVmax ratio was only significantly correlated with the expression of MACC1 in hepatic metastasis (r = 0.770, P = 0.0013).

Conclusions

Early screening with 18F-FLT and 18F-FMISO tracers has important clinical value for the efficient diagnosis and treatment of colorectal cancer liver metastases.
Literature
1.
go back to reference Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin. 2018;68(6):394-424.CrossRef Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin. 2018;68(6):394-424.CrossRef
2.
go back to reference Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality[J].Gut. 2017;66(4):683–91. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality[J].Gut. 2017;66(4):683–91.
3.
go back to reference Bae SH, Moon SK, Kim YH, Cho KH, Shin EJ, Lee MS, et al. Feasibility and response of helical tomotherapy in patients with metastatic colorectal cancer[J]. Radiat Oncol J. 2015;33(4):320-7.CrossRef Bae SH, Moon SK, Kim YH, Cho KH, Shin EJ, Lee MS, et al. Feasibility and response of helical tomotherapy in patients with metastatic colorectal cancer[J]. Radiat Oncol J. 2015;33(4):320-7.CrossRef
4.
go back to reference Kawai K, Tamura K, Sakata I, Ishida J, Nagata M, Tsukada H, et al. A new in vivo model to analyze hepatic metastasis of the human colon cancer cell line HCT116 in NOD/Shi-scid/IL-2Rgamma(null) (NOG) mice by (18)F-FDG PET/CT[J]. Oncol Rep. 2013;29(2):464-8.CrossRef Kawai K, Tamura K, Sakata I, Ishida J, Nagata M, Tsukada H, et al. A new in vivo model to analyze hepatic metastasis of the human colon cancer cell line HCT116 in NOD/Shi-scid/IL-2Rgamma(null) (NOG) mice by (18)F-FDG PET/CT[J]. Oncol Rep. 2013;29(2):464-8.CrossRef
5.
go back to reference Cheng Z, Wei R, Wu C, Qing H, Jiang X, Lu H, et al. Ex-vivo biodistribution and micro-PET/CT imaging of 18F-FDG, 18F-FLT, 18F-FMISO, and 18F-AlF-NOTA-PRGD2 in a prostate tumor-bearing nude mouse model[J]. Nucl Med Commun. 2015;36(9):914-21.CrossRef Cheng Z, Wei R, Wu C, Qing H, Jiang X, Lu H, et al. Ex-vivo biodistribution and micro-PET/CT imaging of 18F-FDG, 18F-FLT, 18F-FMISO, and 18F-AlF-NOTA-PRGD2 in a prostate tumor-bearing nude mouse model[J]. Nucl Med Commun. 2015;36(9):914-21.CrossRef
6.
go back to reference Bejot R, Kersemans V, Kelly C, Carroll L, King RC, Gouverneur V, et al. Pre-clinical evaluation of a 3-nitro-1,2,4-triazole analogue of [18F]FMISO as hypoxia-selective tracer for PET[J]. Nucl Med Biol. 2010;37(5):565-75.CrossRef Bejot R, Kersemans V, Kelly C, Carroll L, King RC, Gouverneur V, et al. Pre-clinical evaluation of a 3-nitro-1,2,4-triazole analogue of [18F]FMISO as hypoxia-selective tracer for PET[J]. Nucl Med Biol. 2010;37(5):565-75.CrossRef
7.
go back to reference Shen G, Ma H, Pang F, Ren P, Kuang A. Correlations of 18F-FDG and 18F-FLT uptake on PET with Ki-67 expression in patients with lung cancer: a meta-analysis[J]. Acta Radiol. 2018;59:188195. Shen G, Ma H, Pang F, Ren P, Kuang A. Correlations of 18F-FDG and 18F-FLT uptake on PET with Ki-67 expression in patients with lung cancer: a meta-analysis[J]. Acta Radiol. 2018;59:188195.
8.
go back to reference Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells[J]. J Nucl Med. 2002;43(9):1210-7.PubMed Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells[J]. J Nucl Med. 2002;43(9):1210-7.PubMed
9.
go back to reference Buck AK, Halter G, Schirrmeister H, Kotzerke J, Wurziger I, Glatting G, et al. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG[J]. J Nucl Med. 2003;44(9):1426-31.PubMed Buck AK, Halter G, Schirrmeister H, Kotzerke J, Wurziger I, Glatting G, et al. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG[J]. J Nucl Med. 2003;44(9):1426-31.PubMed
10.
go back to reference Francis DL, Freeman A, Visvikis D, Costa DC, Luthra SK, Novelli M, et al. In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography[J]. Gut. 2003;52(11):1602-6.CrossRef Francis DL, Freeman A, Visvikis D, Costa DC, Luthra SK, Novelli M, et al. In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography[J]. Gut. 2003;52(11):1602-6.CrossRef
11.
go back to reference van Westreenen HL, Cobben DC, Jager PL, van Dullemen HM, Wesseling J, Elsinga PH, et al. Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer[J]. J Nucl Med. 2005;46(3):400-4.PubMed van Westreenen HL, Cobben DC, Jager PL, van Dullemen HM, Wesseling J, Elsinga PH, et al. Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer[J]. J Nucl Med. 2005;46(3):400-4.PubMed
12.
go back to reference Stein U, Walther W, Arlt F, Schwabe H, Smith J, Fichtner I, et al. MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis[J]. Nat Med. 2009;15(1):59-67.CrossRef Stein U, Walther W, Arlt F, Schwabe H, Smith J, Fichtner I, et al. MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis[J]. Nat Med. 2009;15(1):59-67.CrossRef
13.
go back to reference Koelzer VH, Herrmann P, Zlobec I, Karamitopoulou E, Lugli A, Stein U. Heterogeneity analysis of Metastasis Associated in Colon Cancer 1 (MACC1) for survival prognosis of colorectal cancer patients: a retrospective cohort study[J]. BMC Cancer. 2015;15:160.CrossRef Koelzer VH, Herrmann P, Zlobec I, Karamitopoulou E, Lugli A, Stein U. Heterogeneity analysis of Metastasis Associated in Colon Cancer 1 (MACC1) for survival prognosis of colorectal cancer patients: a retrospective cohort study[J]. BMC Cancer. 2015;15:160.CrossRef
14.
go back to reference Chen S, Zong ZH, Wu DD, Sun KX, Liu BL, Zhao Y. The role of metastasis-associated in colon cancer 1 (MACC1) in endometrial carcinoma tumorigenesis and progression[J]. Mol Carcinog. 2017;56:1361-71.CrossRef Chen S, Zong ZH, Wu DD, Sun KX, Liu BL, Zhao Y. The role of metastasis-associated in colon cancer 1 (MACC1) in endometrial carcinoma tumorigenesis and progression[J]. Mol Carcinog. 2017;56:1361-71.CrossRef
15.
go back to reference Stein U, Burock S, Herrmann P, Wendler I, Niederstrasser M, Wernecke KD, et al. Circulating MACC1 transcripts in colorectal cancer patient plasma predict metastasis and prognosis[J]. PLoS One. 2012;7(11):e49249.CrossRef Stein U, Burock S, Herrmann P, Wendler I, Niederstrasser M, Wernecke KD, et al. Circulating MACC1 transcripts in colorectal cancer patient plasma predict metastasis and prognosis[J]. PLoS One. 2012;7(11):e49249.CrossRef
16.
go back to reference Zhen T, Dai S, Li H, Yang Y, Kang L, Shi H, et al. MACC1 promotes carcinogenesis of colorectal cancer via beta-catenin signaling pathway[J]. Oncotarget. 2014;5(11):3756-69.CrossRef Zhen T, Dai S, Li H, Yang Y, Kang L, Shi H, et al. MACC1 promotes carcinogenesis of colorectal cancer via beta-catenin signaling pathway[J]. Oncotarget. 2014;5(11):3756-69.CrossRef
17.
go back to reference Schmid F, Wang Q, Huska MR, Andrade-Navarro, MA, Lemm, M, Fichtner, I, et al. SPON2, a newly identified target gene of MACC1, drives colorectal cancer metastasis in mice and is prognostic for colorectal cancer patient survival[J]. Oncogene. 2016;35(46):5942-52.CrossRef Schmid F, Wang Q, Huska MR, Andrade-Navarro, MA, Lemm, M, Fichtner, I, et al. SPON2, a newly identified target gene of MACC1, drives colorectal cancer metastasis in mice and is prognostic for colorectal cancer patient survival[J]. Oncogene. 2016;35(46):5942-52.CrossRef
18.
go back to reference Lucarelli G, Rutigliano M, Bettocchi C, Palazzo S, Vavallo A, Galleggiante V, et al. Spondin-2, a secreted extracellular matrix protein, is a novel diagnostic biomarker for prostate cancer[J]. J Urol. 2013; 190(6):2271-7.CrossRef Lucarelli G, Rutigliano M, Bettocchi C, Palazzo S, Vavallo A, Galleggiante V, et al. Spondin-2, a secreted extracellular matrix protein, is a novel diagnostic biomarker for prostate cancer[J]. J Urol. 2013; 190(6):2271-7.CrossRef
19.
go back to reference Zhang MY, Jiang HJ, Zhang RJ, Xu HL, Jiang H, Pan WB, et al. Noninvasive evaluation of 18F-FDG/18F-FMISO-based Micro PET in monitoring hepatic metastasis of colorectal cancer[J]. Sci Rep.2018;8(1):17832.CrossRef Zhang MY, Jiang HJ, Zhang RJ, Xu HL, Jiang H, Pan WB, et al. Noninvasive evaluation of 18F-FDG/18F-FMISO-based Micro PET in monitoring hepatic metastasis of colorectal cancer[J]. Sci Rep.2018;8(1):17832.CrossRef
20.
go back to reference Sato M, Hirose K, Kashiwakura I, Aoki M, Kawaguchi H, Hatayama Y, et al. LW6, a hypoxia-inducible factor 1 inhibitor, selectively induces apoptosis in hypoxic cells through depolarization of mitochondria in A549 human lung cancer cells[J]. Mol Med Rep. 2015;12(3):3462-8.CrossRef Sato M, Hirose K, Kashiwakura I, Aoki M, Kawaguchi H, Hatayama Y, et al. LW6, a hypoxia-inducible factor 1 inhibitor, selectively induces apoptosis in hypoxic cells through depolarization of mitochondria in A549 human lung cancer cells[J]. Mol Med Rep. 2015;12(3):3462-8.CrossRef
21.
go back to reference Qiu J, Huang P, Liu Q, Hong J, Li B, Lu C, et al. Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma[J]. J Transl Med. 2011;9:166.CrossRef Qiu J, Huang P, Liu Q, Hong J, Li B, Lu C, et al. Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma[J]. J Transl Med. 2011;9:166.CrossRef
22.
go back to reference Shimokawa H, Uramoto H, Onitsuka T, Chundong G, Hanagiri T, Oyama T, Y et al. Overexpression of MACC1 mRNA in lung adenocarcinoma is associated with postoperative recurrence[J]. J Thorac Cardiovasc Surg. 2011;141:895–8. Shimokawa H, Uramoto H, Onitsuka T, Chundong G, Hanagiri T, Oyama T, Y et al. Overexpression of MACC1 mRNA in lung adenocarcinoma is associated with postoperative recurrence[J]. J Thorac Cardiovasc Surg. 2011;141:895–8.
23.
go back to reference Anderson GL, McIntosh M, Wu L, Barnett M, Goodman G, Thorpe JD, et al. Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study[J]. J Natl Cancer Inst. 2010; 102(1):26-38.CrossRef Anderson GL, McIntosh M, Wu L, Barnett M, Goodman G, Thorpe JD, et al. Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study[J]. J Natl Cancer Inst. 2010; 102(1):26-38.CrossRef
24.
go back to reference Barbieri CE. Evolution of novel biomarkers for detection of prostate cancer[J]. J Urol. 2013; 190(6):1970-1.CrossRef Barbieri CE. Evolution of novel biomarkers for detection of prostate cancer[J]. J Urol. 2013; 190(6):1970-1.CrossRef
25.
go back to reference Pesson M, Volant A, Uguen A, Trillet K, De La Grange P, Aubry M, et al. A gene expression and pre-mRNA splicing signature that marks the adenomaadenocarcinoma progression in colorectal cancer[J]. PLoS One. 2014; 9(2):e87761.CrossRef Pesson M, Volant A, Uguen A, Trillet K, De La Grange P, Aubry M, et al. A gene expression and pre-mRNA splicing signature that marks the adenomaadenocarcinoma progression in colorectal cancer[J]. PLoS One. 2014; 9(2):e87761.CrossRef
26.
go back to reference Kirchner J, Schaarschmidt BM, Kour F, Sawicki LM, Martin O, Bode J, et al. Incidental 18F-FDG uptake in the colon: value of contrast-enhanced CT correlation with colonoscopic findings.[J].Eur J Nucl Med Mol Imaging.2020,47(4):778–786. Kirchner J, Schaarschmidt BM, Kour F, Sawicki LM, Martin O, Bode J, et al. Incidental 18F-FDG uptake in the colon: value of contrast-enhanced CT correlation with colonoscopic findings.[J].Eur J Nucl Med Mol Imaging.2020,47(4):778–786.
27.
go back to reference Wang L, Wu Y, Lin L, Liu P, Huang H, Liao W, et al. Metastasis-associated in colon cancer-1 upregulation predicts a poor prognosis of gastric cancer, and promotes tumor cell proliferation and invasion[J]. Int J Cancer. 2013;133(6):1419-30.CrossRef Wang L, Wu Y, Lin L, Liu P, Huang H, Liao W, et al. Metastasis-associated in colon cancer-1 upregulation predicts a poor prognosis of gastric cancer, and promotes tumor cell proliferation and invasion[J]. Int J Cancer. 2013;133(6):1419-30.CrossRef
28.
go back to reference Yamamoto H, Miyoshi N, Mimori K, Hitora T, Tokuoka M, Fujino S, et al. MACC1 expression levels as a novel prognostic marker for colorectal cancer[J]. Oncol Lett. 2014;8(5):2305-9.CrossRef Yamamoto H, Miyoshi N, Mimori K, Hitora T, Tokuoka M, Fujino S, et al. MACC1 expression levels as a novel prognostic marker for colorectal cancer[J]. Oncol Lett. 2014;8(5):2305-9.CrossRef
29.
go back to reference Liao CH, Yeh SC, Huang YH, Chen RN, Tsai MM, Chen WJ, et al. Positive regulation of spondin 2 by thyroid hormone is associated with cell migration and invasion[J]. Endocr Relat Cancer. 2010; 17(1):99-111.CrossRef Liao CH, Yeh SC, Huang YH, Chen RN, Tsai MM, Chen WJ, et al. Positive regulation of spondin 2 by thyroid hormone is associated with cell migration and invasion[J]. Endocr Relat Cancer. 2010; 17(1):99-111.CrossRef
30.
go back to reference Lu H, Feng Y, Hu Y, Guo Y, Liu Y, Mao Q, et al. Spondin 2 promotes the proliferation, migration and invasion of gastric cancer cells[J].J Cell Mol Med.2020,24(1):98–113. Lu H, Feng Y, Hu Y, Guo Y, Liu Y, Mao Q, et al. Spondin 2 promotes the proliferation, migration and invasion of gastric cancer cells[J].J Cell Mol Med.2020,24(1):98–113.
31.
go back to reference Qian X, Li C, Pang B, Xue M, Wang J, Zhou J. Spondin-2 (SPON2), a more prostate-cancer-specific diagnostic biomarker[J]. PLoS One. 2012; 7(5):e37225.CrossRef Qian X, Li C, Pang B, Xue M, Wang J, Zhou J. Spondin-2 (SPON2), a more prostate-cancer-specific diagnostic biomarker[J]. PLoS One. 2012; 7(5):e37225.CrossRef
32.
go back to reference Carvalho B, Sillars-Hardebol AH, Postma C, Mongera S, Terhaar Sive Droste J, Obulkasim A, et al. Colorectal adenoma to carcinoma progression is accompanied by changes in gene expression associated with ageing, chromosomal instability, and fatty acid metabolism[J]. Cell Oncol. 2012; 35(1):53–63. Carvalho B, Sillars-Hardebol AH, Postma C, Mongera S, Terhaar Sive Droste J, Obulkasim A, et al. Colorectal adenoma to carcinoma progression is accompanied by changes in gene expression associated with ageing, chromosomal instability, and fatty acid metabolism[J]. Cell Oncol. 2012; 35(1):53–63.
33.
go back to reference Zhang Q, Wang XQ, Wang J, Cui SJ, Lou XM, Yan B, et al. Upregulation of spondin-2 predicts poor survival of colorectal carcinoma patients[J]. Oncotarget. 2015;6(17):15095-110.CrossRef Zhang Q, Wang XQ, Wang J, Cui SJ, Lou XM, Yan B, et al. Upregulation of spondin-2 predicts poor survival of colorectal carcinoma patients[J]. Oncotarget. 2015;6(17):15095-110.CrossRef
34.
go back to reference Gu G, Dustin D, Fuqua SA. Targeted therapy for breast cancer and molecular mechanisms of resistance to treatment[J]. Curr Opin Pharmacol. 2016;31:97-103.CrossRef Gu G, Dustin D, Fuqua SA. Targeted therapy for breast cancer and molecular mechanisms of resistance to treatment[J]. Curr Opin Pharmacol. 2016;31:97-103.CrossRef
35.
go back to reference de Castro J, Tagliaferri P, de Lima VCC, Ng S, Thomas M, Arunachalam A, et al. Systemic therapy treatment patterns in patients with advanced non-small cell lung cancer (NSCLC): PIvOTAL study[J]. Eur J Cancer Care (Engl). 2017;26(6). de Castro J, Tagliaferri P, de Lima VCC, Ng S, Thomas M, Arunachalam A, et al. Systemic therapy treatment patterns in patients with advanced non-small cell lung cancer (NSCLC): PIvOTAL study[J]. Eur J Cancer Care (Engl). 2017;26(6).
Metadata
Title
Screening of radiotracer for diagnosis of colorectal cancer liver metastasis based on MACC1-SPON2
Authors
Hao Jiang
Wei Guo
Kuan Huang
Huijie Jiang
Rongjun Zhang
Hongbo Hu
Xue Lin
Song Wang
Publication date
01-07-2021
Publisher
Springer US
Published in
Abdominal Radiology / Issue 7/2021
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-021-03015-w

Other articles of this Issue 7/2021

Abdominal Radiology 7/2021 Go to the issue

Classics in Abdominal Radiology

The “pie-in-the-sky” bladder

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.